Cotransfer of thyroid-specific transcription factor (TTF)-1 and Pax-8 gene to tumor cells, resulting in the re-expression of iodide metabolism-associated proteins, such as sodium iodide symporter (NIS), thyroglobulin (Tg), thyroperoxidase (TPO), offers the possibility of radioiodine therapy to non-iodide-concentrating tumor because the expression of iodide metabolism-associated proteins in thyroid are mediated by the thyroid transcription factor TTF-1 and Pax-8. The human TTF-1 and Pax-8 gene were transducted into the human thyroid carcinoma (K1 and F133) cells by the recombinant adenovirus, AdTTF-1 and AdPax-8. Re-expression of NIS mRNA and protein, but not TPO and Tg mRNA and protein, was detected in AdTTF-1-infected F133 cells, following with increasing radioiodine uptake (6.1 --7.4 times), scarcely iodide organification and rapid iodide efflux (t 1/2 E8-min in vitro, t 1/2 E4.7-h in vivo). On contrast, all of the re-expression of NIS, TPO and Tg mRNA and proteins were detected in F133 cells coinfected with AdTTF-1 and AdPax-8. AdTTF-1-and AdPax-8-coinfected K1 and F133 cells could effectively accumulate radioiodine (6.6 --7.5 times) and obviously retarded radioiodine retention (t 1/2 E25 --30-min in vitro, t 1/2 E12-h in vivo) (Po0.05). Accordingly, the effect of radioiodine therapy of TTF-1 and Pax-8 cotransducted K1 and F133 cells (21 --25% survival rate in vitro) was better than that of TTF-1-transducted cells (40% survival rate in vitro) (Po0.05). These results indicate that single TTF-1 gene transfer may have limited efficacy of radioiodine therapy because of rapid radioiodine efflux. The cotransduction of TTF-1 and Pax-8 gene, with resulting NISmediated radioiodine accumulation and TPO and Tg-mediated radioiodine organification and intracellular retention, may lead to effective radioiodine therapy of thyroid carcinoma.
INTRODUCTION
Radioiodide therapy is an effective approach for treatment of differentiated thyroid carcinoma and their metastases. Radioiodide therapy is based on the capacity of thyroid carcinoma cells to trap and concentrate iodide, which is completed by the cooperation of thyroid-specific proteins, such as the sodium iodide symporter (NIS), thyroglobulin (Tg) and thyroperoxidase (TPO). 1 However, to anaplastic thyroid carcinoma and any other nonthyroid carcinoma, which shows no radioiodine accumulation, radioiodide therapy is not suitable to them. It confines the extensive application of radioiodide therapy in clinic. NISmediated iodide uptake in normal and well-differentiated neoplastic thyroid cells. TPO catalyzes oxidation of iodide ion, iodination of tyrosine residues of Tg and coupling of iodotyrosines to generate iodothyronines T3 and T4 and, thus promotes iodide retention within thyroid cells. It is postulated that re-expression of these iodide metabolic proteins would enable non-iodideconcentration tumor to acquire/restore the capacity of radioiodine concentration, which make it possible to treat non-iodide-concentration tumor with radioiodine.
Transcription factors have a pivotal role in the determination and maintenance of cellular phenotype. The activity of transcription factors is considered as the main switch to regulate gene expression. 2 The expression of those thyroid-specific proteins is controlled by the combination of specific transcription factors with the respective promoters/enhancers of those genes. In thyroid follicular cells, three thyroid-specific transcription factors (TTFs) have been identified: TTF-1, TTF-2 and Pax-8, which regulate the transcriptional activity of Tg and other thyroid-specific genes, such as TPO and thyrotropin receptor (TSHr). 3 TTF-1 is a homeodomaincontaining protein expressed in embryonic diencephalons, thyroid and lung. 4 Pax-8 belongs to the Pax family of paired domaincontaining genes and is expressed in the kidney, the developing excretory system and the thyroid. 5 Three TTF-1-binding sites are present in the Tg and the TPO promoter. TTF-1 could activate transcription from the Tg promoter and, at a much low extent, from TPO promoter in both thyroid and nonthyroid cells. 6 Pax-8 binds to a single site on the Tg and on the TPO promoters and, in both case, the Pax-8-binding site overlaps with that of TTF-1. 7 In addition, TTF-1 could activated the rat NIS promoter by a direct interaction with its enhancer region 8 and, Pax-8 has two binding sites of rat NIS upstream enhancer and has an important role in the expression of NIS gene. 9 In addition to their expression in the follicular thyroid cells, TTF-1 and Pax8 also expressed in the lung and kidney, respectively. However, the two factors are present together only in the thyroid follicular cell, suggesting that their combination could have a role in the expression of the thyroidspecific phenotype. 10 Ros et al. 11 reported that TTF-1 and Pax8 were expressed in well-differentiated thyroid adenomas and that their expression decreased in less differentiated papillary and follicular carcinomas and was lost in undifferentiated anaplastic carcinomas. They also affirmed that the expression of the thyroid-specific genes Tg, TPO and TSHr and their transcription factors, TTF-1 and Pax8, was lost in thyroid cells derived from follicular papillary and anaplastic human carcinomas. Fabbro et al. 10 found that, in anaplastic thyroid carcinomas, the absence of TTF-1 was associated with the absence of Tg gene expression. Both transcription factors directly interact and synergistically activate thyroid-specific transcription. 6, 12 TTF-1 and Pax-8 cooperate with several ubiquitous transcription factors, forming complexes on the regulatory region of specific genes. 13, 14 Miccadei et al. 15 reported that TTF-1 and Pax-8 cooperatively activated TPO and Tg gene transcription and their synergistic activity require the cross-talk between enhancer and gene prompter. Furthermore, Altmann et al. 16 found that the transcriptional activation of hTg, hTPO and rNIS gene was low in cells expression either hPax-8 or dTTF-1 alone. In contrast, the activation of hTg promoter and hTPO promoter and, to a lesser extent, of rNIS promoter was significantly activated in cell lines expression both TTF-1 and Pax-8.
To extend radioiodide therapy to undifferentiated thyroid carcinoma and other nonthyroid carcinoma, in this study we constructed the adenovirus vectors (AdTTF-1 and AdPax-8) for TTF-1 and Pax-8 gene transfer to induce reactivation of endogenous thyroid-specific genes. The ability of TTF-1 and Pax-8 to induce re-expression of thyroid-specific genes, NIS, Tg and TPO, was investigated in human thyroid carcinoma cells and, then, radioiodine uptake and retention reactivated by TTF-1 and Pax-8 was examined in vitro or in vivo. The results reported here indicated that combining transfer of TTF-1 and Pax-8 gene was an available strategy to promote radioiodine therapy of non-iodide-concentration tumor.
MATERIALS AND METHODS

Cell culture
K1 and F133 cells were purchased from European Collection of Animal Cell Cultures (ECACC, Wiltshire, UK) and HEK293 cells were kindly provided by Pathology Laboratory of West China Hospital, Sichuan University. The human papillary thyroid carcinoma cell line K1 has very low iodide uptake and NIS mRNA and protein in it is hardly detectable. 17 The human follicular thyroid carcinoma cell line F133 expresses Tg, and TSHR, but not TPO. The cell line does not take up iodide and hNIS mRNA expression in it is hardly detectable, too. 18 All cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) medium, high glucose content (Gibco, Carlsbad, CA) with 10% fetal bovine serum, 2 mmol l --1 L-glutamine, 100 IU ml --1 penicillin G and 100 mg ml --1 streptomycin sulfate. Cells were maintained at 37 1C and 5% CO 2 in an incubator with 95% humidity. The culture medium was replaced every second day and cells were passaged at 90% confluency using 0.05% trypsin (Invitrogen Life Technologies, Carlsbad, CA, USA).
Recombinant adenovirus
The full-length human TTF-1 complementary DNA (nucleotides 83 --1288 bp, GeneBank Acession Number: NM_001079668) and the full-length human Pax-8 complementary DNA (nucleotides 167 --1519 bp, GeneBank Acession Number: NM_003466) were respectively removed from the pMD-18T simple vector (reconstructed by Invitrogen Life Technologies) by restriction digestion using KpnI and HindIII, agarose gel purified and ligated into pShuttle plasmid (pAdTrack-CMV) of the AdEasier adenovirus system resulting in pAdTrack-TTF-1 and pAdTrack-Pax-8. Subsequently, homologous recombination of pAdTrack-TTF-1/pAdTrack-Pax-8 plasmid and pAdEasy-1 plasmid were performed in the bacteria BJ5183 Escherichia coli. The recombined adenovirus pAdTTF-1 and pAdPax-8 plasmid were agarose-gel purified and confirmed by PCR and DNA sequencing. The pAdTTF-1 and pAdPax-8 were digested by 4 mg PacI and, then they were packaged using Lipofectamine2000 (Invitrogen, Carlsbad, CA) and respectively transfected into HEK293 cells according to the standard procedure. AdTTF-1 and AdPax-8 virus propagated in HEK293 cells. After two-step purification on CsCl gradients, viral stocks were desalted using Pharmacia G50 columns (Orsay, France) and frozen at 80 1C in 10 mM Tris-HCl (pH 7.5) containing 2.5% glycerol. Viral titers were determined by plaque assays using cultured HEK293 cells and were expressed as plaque-forming unit (PFU) ml --1 .
Analysis of mRNA by reverse transcriptase-PCR Total RNA was prepared from cell lines using Trizol (Invitrogen) and quantitated spectrophotometrically. Reverse transcriptase-PCR was performed using 2 mg of total RNA. The initial reverse transcription was at 42 1C for 1 h in 20 ml solution containing M-MLV Reverse Transcriptase 100 U (Toyobo, Osaka, Japan), 4 ml 5 Â first brand buffer, 0.1 mM oligo (deoxythymidine) 18 primer, 2 ml dNTPs mix (10 mM of each), 1 ml dithiothreitol (0.1 ml) and 6.0 ml ddH 2 O. Complementary DNA aliquots equivalent to 100 ng RNA were subjected to PCR using Taq DNA polymerase (BioRule Biology Techonlogies, Shanghai, China). The primers and conditions used and the expected sizes of the target genes were shown in Table 1 . For target genes amplification, cycling conditions were 5 min at 95 1C for pre-denaturation, 30 cycles of 45 s at 94 1C for denaturation, 30 s at various temperatures, as shown in Table 1 for annealing, 90 s at 72 1C for extension followed by 10 min at 72 1C for final extension. PCR products (25 ml) from each reaction were analyzed by 1.8 agarose/ethidium bromide gel electrophoresis. All amplification reactions were performed in triplicate and the relative expression levels were calculated as the density of the product of the respective target genes divided by that of the control gene, b-actin.
Western blot analysis
Total proteins (50 mg) prepared from transfected F133 cells were denaturated by water bath with 2 Â sodium dodecyl sulfate gel loading buffer (TrisHCl (pH 6.8) 100 mM, 4% sodium dodecyl sulfate, 0.2% bromchlorphenol Iodide uptake and efflux assay K1 and F133 cells were plated into six-well plates the day before infection at a seeding density of 1.0 Â 10 6 cells per well, to reach 50 --70% confluence for infection. Cells were washed twice with phosphate-buffered saline (PBS) and incubated in serum-free medium. The virus at MOI (appropriate multiplicity of infection) in 1 ml serum-free medium were added to each well for 2 h, and then the serum-free medium were changed into complete medium. After infection for 48 h, cells were washed twice with PBS and incubated in 1 ml serum-free DMEM containing 3.7 kBq 125 I, with or without 300 mM NaClO 4 . Following incubation at 37 1C for 5 --120 min, the medium containing 125 I were removed and the cells were washed twice with PBS. The cell-associated radioactivity at different time point was measured with a g-counter.
Iodide efflux studies were performed after K1 and F133 cells were infected with adenoviral as described above. Cells per well were washed twice with PBS and incubated in 1 ml serum-free DMEM containing 3.7 kBq 125 I at 37 1C for 1 h. Cells were washed twice with PBS, and then 1 ml serum-free DMEM without radioactivity was added per well. The serumfree DMEM was replaced every 5 min for 30 min and the radioactivity of 125 I in the collected medium was measured with a g-counter. After the last time point, trapped 125 I were removed from cells and were measured with a g-counter. Total radioactivity at the beginning of the efflux study (100%) were calculated by summing radioactivity of collected medium at different time point and final radioactivity of cells.
Radioiodine organification assay in vitro
K1 and F133 cells were infected with adenovirus for 24 h as previously described. Methimazole (MMI, 500 mM), a TPO-specific inhibitor that acts by uncoupling TPO-catalyzed oxidative iodination, was added in medium. After incubation in MMI-containing medium for 24 h, cells were then incubated in 1 ml DMEM (without serum) containing 3.7 kBq 125 I at 37 1C for 1 h. Medium containing 125 I was removed, and cells were washed twice with PBS. Proteins in the cell lysates were precipitated by the addition of 0.5 ml 40% trichloroacetic acid (final concentration, 20%). Precipitated proteins were collected by centrifugation at 3300 Â g for 30 min and were washed twice with PBS. Radioactivity in the pellets was measured with a g-counter.
Clonogenic assay in vitro 
Statistical analysis
All experiments were carried out in triplicates or more under the same conditions. Results are presented as means±s.d. Statistical significance was tested using Student's t-test. Po0.05 was considered statistically significant. (Figure 3) . The iodide accumulation in K1 and F133 cells induced by AdTTF-1 and AdPax-8 were almost completely inhibited by sodium perchlorate. These results suggest that TTF-1 and Pax-8 could synergistically promote radioiodine uptake in thyroid carcinoma cells by inducing the expression of NIS protein.
RESULTS
Expression of NIS
AdTTF-1 and AdPax-8-induced radioiodine organification As AdTTF-1 and AdPax-8 could induce the expression of Tg and TPO proteins (Figure 2 
.p.m., Po0.01) and AdTTF-1-infected K1 cells (2170±648 c.p.m., Po0.01), respectively. Meanwhile, the proteinbound radioiodine in AdTTF-1-and AdPax-8-coinfected F133 cells was 11 995 ± 865 c.p.m., and it was about 11.1-and 5.3-fold higher than that of AdCMV-infected F133 cells (990 ± 181 c.p.m., Po0.01) and AdTTF-1-infected F133 cells (1893±535 c.p.m., Po0.01), respectively. The protein-bound radioiodine induced by AdTTF-1 and AdPax-8 were very sensitive to MMI pre-treatment and it were almost completely inhibited by MMI (Po0.01). These results showed that TPO induced by AdTTF-1 and AdPax-8 catalyzed iodide organification in K1 and F133 cells (Figure 4 ).
AdTTF-1 and AdPax-8 restrained iodide efflux
We have demonstrated that AdTTF-1 and AdPax-8 could promote iodide uptake (Figure 3 ) and induce iodide organification (Figure 4 ) in K1 and F133 cells. To determine whether TTF-1 and Pax-8 cotransfer could prolong radioiodine retention in K1 and F133 cells, we performed a radioiodine efflux assay. AdTTF-1-and AdPax-8-infected K1 and F133 cells were exposed to radioiodine, and the release of radioactivity into the medium was monitored every 5 min. There was a rapid efflux of radioactivity from K1 and F133 cells infected with either AdTTF-1 (t 1/2 E8 min) or AdCMV (t 1/2 E6 min), and cellular radioactivity was almost completely released into the medium over 30 min. In contrast, iodide efflux was prolonged in AdTTF-1-and AdPax-8-coinfected K1 and F133 cells (t 1/2 E25 and 30 min, respectively) ( Figure 5 ). These results indicate that TTF-1 and Pax-8 cotransfer could effectively restrain iodide efflux and prolong radioiodine retention in K1 and F133 cells.
Clonogenic assay in vitro
We want to know therapeutic effect of radioiodine on K1 and F133 cells co-transfected with AdTTF-1 and AdPax-8 because AdTTF-1 and AdPax-8 induced iodide uptake and prolonged iodide retention in K1 and F133 cells (Figures 3 and 5) . After 131 I treatment, clonogenic assay were performed and results are shown in Figure 6 . Following exposure to 131 I, about 20% of AdCMV-infected K1 or F133 cells were nonselectively killed. After 131 I treatment, the survival rate of AdTTF-1-infected K1 and F133 cells were 40% and 43%, respectively, and that of AdTTF-1-and AdPax-8-coinfected K1 and F133 cells were 21% and 25%, respectively, which were apparently lower than that of AdCMVinfected K1 or F133 cells (Po0.05). Moreover, the survival rate of K1 and F133 cells coinfected with AdTTF-1 and AdPax-8 were and AdPax-8 for 2 h, and then incubated with adenovirus-free medium for 48 h. All cells were incubated in serum-free medium containing 3.7 kBq Na 125 I for 1 h. Cells were washed twice with phosphate-buffered saline (PBS), and the medium was replaced with nonradioactive medium every 5 min. The radioactivity in the replaced medium was measured with a g-counter. After the last medium was removed, the cells were extracted. The total radioactivity present at the initiation of the efflux study (100%) was calculated by adding the counts in the final cells to the medium counts at various time point. Data are expressed as the mean±s.e.m. (n ¼ 6).
obviously lower than that of K1 and F133 cells infected with AdTTF-1 (Po0.05). These data demonstrate that coinfection with AdTTF-1 and AdPax-8 obviously enhanced the effect of radioiodine therapy of K1 and F133 cells.
TTF-1 and Pax-8 induce iodide accumulation in vivo
We demonstrated that AdTTF-1 and AdPax-8 could promote radioiodine accumulation and prolong radioiodine retention in K1 and F133 tumor cells in vitro. In order to extend those results to an in vivo model, biodistribution of 125 I was performed on F133-bearing mice. The quantitation of the 125 I uptake (%ID g --1 ) in the tumors and other tissues was evaluated at 1, 2, 4, 8 and 12 h after 125 I administration. The biodistribution data of radioiodine in F133-bearing mice after intratumoral injection of AdTTF-1, AdTTF-1 and AdPax-8, were summarized in Figure 7 . The AdCMVinfected F133 tumor accumulated a lower amount of the radioiodine than did AdTTF-1-infected F133 tumor or AdTTF-1-and AdPax-8-coinfected F133 tumor. The radioactivity in AdCMVinfected tumor was faintly increased, thereafter, it gradually decreased. 5 .64 ± 0.67%ID g --1 radioiodine still remained in it, which were obviously higher than that in AdTTF-1-infected tumor (Po0.05). The average biological half-life of radioiodine in F133 tumor infected with AdCMV, AdTTF-1, AdTTF-1 and AdPax-8 was 3.75, 4.7 and up to 12 h, respectively.
All of other organs accumulated slight radioiodine, no 45.8% ID g --1 (intestine) at all time, except thyroid and stomach. The tumor/blood and tumor/muscle 125 I uptake ratios of AdTTF-1-infected F133 tumor were 1.81 ± 0.46 and 3.59 ± 0.87 at 8 h after 125 I administration, respectively, which were higher than that of AdCMV-infected F133 tumor (0.68±0.16 and 1.34±0.41, respectively) (Po0.05). Comparatively, the tumor/blood and tumor/ muscle 125 I uptake ratios of F133 tumor coinfected with AdTTF-1 and AdPax-8 were 3.42±0.51 and 11.09±1.14 at 8 h after 125 I administration, respectively, which were higher than that of AdTTF-1-or AdCMV-infected F133 tumor (Po0.05). These data demonstrate that AdTTF-1 and AdPax-8 promoted radioiodine accumulation and prolonged radioiodine retention in F133 tumor in vivo.
Tumor imaging Radioiodine uptake in tumor was determined using a g-camera at 2, 4, 8, 12 and 24 h after 131 I injection (Figure 8 ). AdTTF-1-infected F133 tumors accumulated 131 I rapidly and were early visualized at 2 h after 131 I administration. However, they quickly attenuated after 4 h and were hardly visible at 12 h. In contrast, the F133 tumors coinfected with AdTTF-1 and AdPax-8 began to show at 2 h and they were still visualized at 24 h after 131 I administration. Some normal organs expressing NIS (including those of thyroid, stomach) and involved in iodide elimination (bladder) showed clearly. 
DISCUSSION
Distant metastasis is the first primary cause of death to most patients with cancer, because no durative therapy for metastases. In contrast, DTC, even with distant metastases, can be effectively treated by radioiodine because of the unique ability of carcinoma cells to concentrate iodine from plasma. The special property of DTC makes it to be one of the most manageable cancers. 19 It is postulated that re-expression of iodide-metabolic relative proteins would restore/acquire iodine uptake in cancer and enable them be treated by radioiodine. Mandell et al. 20 initially proposed NIS-based radioiodine concentrator gene therapy for extrathyroidal cancer. It has shown that the transfer of NIS gene confers increased radioiodine uptake in thyroid cancer, 21 breast cancer, 22 hepatoma, 23 prostate cancer, 24 and so on. These studies demonstrated that NIS-transducted tumor cells could significantly accumulated radioiodine, and consequently, be selectively killed by radioiodine in vivo and in vitro. 20,24 --26 However, rapid radioiodine efflux form NIS-transfected cells may impact the antitumor efficacy of this therapeutic strategy.
All of the expression of iodide-metabolic relative proteins such as NIS, Tg and TPO in thyroid are regulated by TTF-1 and/or Pax-8. Maybe it is a possible strategy to simultaneously stimulate the expression of NIS, Tg and TPO in tumor cells and, to promote radioiodine uptake and prolong iodide retention in tumor cells at one time, by transfer TTF-1 and/or Pax-8 gene. Our group has found that Pax-8 could activate the expression of TPO and Tg proteins in human thyroid carcinoma cells. The radioiodine uptake was partially restored and T 1/2 of 131 I in thyroid carcinoma cells was apparently prolonged by Pax-8 (data in paper). In the present report, we further co-transferred TTF-1 and Pax-8 gene by adenovirus vectors and discovered that TTF-1 alone could specially induced the expression of NIS and the synergetic effect of TTF-1 and Pax-8 could simultaneously induce the re-expression of NIS, TPO and Tg proteins in human thyroid carcinoma F133 cells. TTF-1 and Pax-8 cotransducted K1 and F133 cells could accumulate more radioiodine and obviously retarded radioiodine efflux than TTF-1-transducted K1 and F133 cells in vitro and in vivo. Consequently, the effect of radioiodine therapy of TTF-1 and Pax-8 co-transducted K1 and F133 cells was better than that of TTF-1-transducted cells.
In this study, we discovered that AdTTF-1 specially activated the expression of NIS in F133 cells, and which were further promoted in TTF-1 and Pax-8 co-transducted F133 cells. Accordingly, the radioiodine uptake was obviously increased in both AdTTF-1-infected and AdTTF-1-and AdPax-8-coinfected K1 and F133 cells. Altmann et al. 16 found that TTF-1 has no induction or a low induction of transcriptional activation of NIS promoter. On the other hand, the activation of rNIS promoter (up to sixfold) were activated in cell lines expression both TTF-1 and Pax-8. However, Furuya et al. 27 found that no detectable NIS expression was shown in thyroid carcinoma (BHP18-21v) cells, regardless of whether they infected with AdTTF-1. But AdTTF-1 induced a small, but significant, iodide accumulation, which was inhibited by sodium perchlorate in BHP18-21v cells. Schmitt et al. 28 also reported that TTF-1 had no influence in the activation of NIS promoter and Pax-8 had a moderate stimulating effect (threefolds) on the NIS promoter in Hela and COS-7 cells. To explain this observations, it could be speculated that the expression of NIS activated by TTF-1 had the cell-specificity because Endo et al. 8 observed that TTF-1 can bind to a minima 5 0 -flanking sequence region (between À291 and À134 bp) of NIS gene extracts from a rat thyroid cell line, FRTL-5 cells, but not BRL-3A rat liver cells, forming a specific DNA-protein complex and causing a significant increase in the transcriptional activity of the promoter of rat NIS gene. Moreover, the study that TTF-1 is a phosphoprotein and phosphorylation is reduced in the Ha-ras-transformed thyroid cells, where TTF-1 is unable to activate transcription from the Tg promoter, suggests a possible mechanisms whereby differential phosphorylation of TTF-1 in different cell types could be responsible for its promoter selection. 29 The therapeutic efficacy of radioiodine is dependent on the radiation dose delivered to the target tissue and, the radiation dose delivered to a tumor is dependent on two factors: the radioactive concentration of 131 I and the effective half-life (T1 30 Rapid radioiodine efflux after sufficient iodide uptake is probably the main problem of NIS-transduction. Although the tumors efficiently concentrated iodide after NIS gene transfer, no effect of 131 I on tumor growth was observed because the rapid iodide efflux from the tumor did not allow the delivery of a radiation dose sufficient to inhibit cell growth. 21, 31, 32 Thus, to efficiently therapy tumor with 131 I by gene transfer, it is mandatory to increase the retention time of iodide in the tumor. An appealing strategy is to mimic the situation existing in the thyroid, that is, to organify the iodide taken up by the tumor. TPO is the main enzyme to catalysis iodide organification in thyroid. Any iodide not organified by TPO will rapidly efflux from thyroid follicular cells. 33 Some researchers try to inhibit iodide efflux by re-expressing TPO in tumor cell. Haberkorn et al. 34 found that the accumulation of iodide was not significantly enhanced and there was no correlation between hTPO expression and enzyme activity in human anaplastic thyroid carcinoma cells transferred human TPO gene. They presumed that the transduction of hTPO gene was not sufficient to restore iodide trapping in non-iodide-concentration tumor cells. After that, Huang et al. 35 transfected non-small cell lung cancer cells with human NIS and TPO genes. They discovered that the combination of NIS and TPO gene transfection, with resulting in NIS-mediated iodide uptake and TPO-mediated organification and intracellular retention of radioiodine, might lead to more effective radioiodine therapy of tumor. However, Boland et al. 36 reported that an increasing in iodide organification could be observed in rat thyroid FRTL-5 cells coinfected with both AdNIS and AdTPO in the presence of exogenous hydrogen peroxide, but the levels of iodide organification obtained were too low to significantly increase the iodide retention time in the target cells. In this study, the expression of Tg and TPO in F133 cell, not like that of NIS, was not promoted by Ad-TTF-1. Besides, while combining with Pax-8, the activating effect of TTF-1 on the expression of Tg and TPO was apparently enhanced. The results of radioiodine organification assay and radioiodine efflux analysis showed that, following with the expression of Tg and TPO, radioiodine organized and radioiodine retention time obviously prolonged in AdTTF-1-and Ad-Pax-8-coinfected F133 cells, comparing with that in AdTTF-1-or Ad-CMV-infected F133 cells. Altmann et al. 16 also reported that TTF-1 could not activate Tg and TPO promoter, but the activation of hTg promoter (up to 23-fold) and hTPO promoter (up to 28-fold) were significantly activated in cell lines expression both TTF-1 and Pax-8. These results indicated efficient iodide organification and retention induced by TTF-1 and Pax-8.
We hope that the efficacy of radioiodine therapy for TTF-1 and Pax-8 co-transfected tumor would improve because the sufficient iodide accumulation and retarded iodide retention were observed in TTF-1 and Pax-8 co-transfected K1 and F133 cells. The data from biodistribution of radioiodine in vivo showed that TTF-1 and Pax-8 cotransducted cancer could accumulate significantly more radioiodine than parental tissue, and comparatively, Ad-TTF-1-and AdPax-8-coinfected F133 and K1 cells were selectively and efficiently killed by radioiodine in vitro. The effective half time of radioiodine in F133 tumor infected Ad-TTF-1 and Ad-Pax-8 was about 12 h, which was obviously shorter than the mean effective half time of radioiodine in DTC (78.8 h). 37 We speculated it was due to the defect of transfer gene technology itself, because it is unlikely to achieve 100% transfection rate in vivo. The powerful gene delivery systems toward clinical application must be performed in further studies. Besides, the combinatorial strategy should be considered to improve the efficacy of radioiodine therapy for tumor following gene transfer.
Another At is regarded as a promising radionuclide for cell-targeted radiotherapy owing to a combination of favorable properties, including short half-life (7.2 h) and decay via a bibranch pathway emitting two a-particle types (6.8 MeV mean energy), leading to deposition of high energy over a short distance (55--88 mm mean tissue range).
211
At uptake is shown to be NIS dependent, with characteristics similar to 131 I uptake. 40 At). 17 In this study, radioiodine rapidly flowed into tumor cells infected AdTTF-1 and AdPax-8 after iodide administration. We speculate that A better understanding of the mechanisms governing iodide transport in the cells may provide better solutions to efficiently improve iodide retention. Indeed, an increased iodide retention time could be obtained by specifically blocking the mechanism controlling iodide efflux. Pendrin is a glycoprotein protein located at the apical membrane of thyrocytes, which is thought to be involved in iodide efflux from the intracellular compartment to the follicular lumen in the thyroid gland. 41 Other proteins (SLC5A8 and chloride channel 5 ClCn5) have been proposed to mediate apical iodide efflux. 42, 43 Functional studies performed in Xenopus oocytes and polarized Madin --Darby canine kidney cells clearly demonstrate that SLC5A8, originally designated as human apical iodide transporter, 42 does not mediate iodide uptake or efflux. 44 Localization of the ClCn5 protein at the apical membrane of thyrocytes and a thyroidal phenotype of the ClCn5-deficient mice that is reminiscent of Pendred syndrome suggest that ClCn5 could be involved in mediating apical iodide efflux or iodide/chloride exchange. 43 This possibility has, as of yet, not been demonstrated by further experimental data.
In conclusion, TTF-1 can specially activate the expression of NIS, resulting in an increasing radioiodine accumulation in K1 and F133 cell. However, no detectable induction of Tg and TPO proteins expression is observed in TTF-1-transducted F133 cell, following limited iodine organification and retention. Comparatively, the synergy of TTF-1 and Pax-8 can simultaneously activate the expression of NIS, Tg and TPO proteins in F133 cells, and induces more significant radioiodine accumulation and obviously radioiodine retention than TTF-1 alone. TTF-1 and Pax-8 cooperatively promote the therapeutic effect of radioiodine on thyroid carcinoma cells. The cotransduction of TTF-1 and Pax-8 gene is a feasible strategy to promote the effect of radioiodine therapy on non-iodide-concentrating tumor. Further studies will concentrate on enhancing the effect of radionuclide therapy conducted by TTF-1 and Pax-8 gene co-transfer through using more powerful therapeutic radionuclides, such as 211 At and 188 Re. In addition, these approaches to improve radioiodine cancer treatment will be advanced by the development of more effective tumor targeted, systemic gene delivery systems. 
